NEW YORK (GenomeWeb News) – Japanese diagnostic firm Sysmex will buy a 34 percent equity stake in bioMérieux’s Japanese subsidiary as part of an agreement to form a joint venture that will market bioMérieux’s in vitro diagnostics products in Japan.
 
The joint venture, which will hold the name Sysmex bioMérieux, will market bioMérieux’s entire product line in Japan beginning April 1. Prior to the agreement, bioMérieux’s Japanese operations were managed by its wholly owned subsidiary bioMérieux Japan.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.